The 36-month beta value for NEO is also noteworthy at 1.64. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
The public float for NEO is 127.02M, and at present, short sellers hold a 4.94% of that float. The average trading volume of NEO on June 04, 2025 was 2.09M shares.
NEO) stock’s latest price update
The stock of Neogenomics Inc (NASDAQ: NEO) has increased by 4.32 when compared to last closing price of 7.17.Despite this, the company has seen a loss of -0.27% in its stock price over the last five trading days. accessnewswire.com reported 2025-06-03 that NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. (“Zeo” or the “Company”) (NASDAQ:NEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEO’s Market Performance
NEO’s stock has fallen by -0.27% in the past week, with a monthly drop of -2.86% and a quarterly drop of -19.91%. The volatility ratio for the week is 2.71% while the volatility levels for the last 30 days are 3.11% for Neogenomics Inc. The simple moving average for the past 20 days is -3.49% for NEO’s stock, with a -43.00% simple moving average for the past 200 days.
Analysts’ Opinion of NEO
Leerink Partners, on the other hand, stated in their research note that they expect to see NEO reach a price target of $9. The rating they have provided for NEO stocks is “Market Perform” according to the report published on April 30th, 2025.
NEO Trading at -12.50% from the 50-Day Moving Average
After a stumble in the market that brought NEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.87% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NEO starting from Kelly Michael Aaron, who purchase 5,000 shares at the price of $7.60 back on May 27 ’25. After this action, Kelly Michael Aaron now owns 5,000 shares of Neogenomics Inc, valued at $38,000 using the latest closing price.
Stone Warren, the Pres & Chief Operating Officer of Neogenomics Inc, purchase 5,700 shares at $8.58 during a trade that took place back on May 12 ’25, which means that Stone Warren is holding 108,280 shares at $48,895 based on the most recent closing price.
Stock Fundamentals for NEO
Current profitability levels for the company are sitting at:
- -0.13 for the present operating margin
- 0.44 for the gross margin
The net margin for Neogenomics Inc stands at -0.12. The total capital return value is set at -0.07. Equity return is now at value -8.57, with -4.79 for asset returns.
Based on Neogenomics Inc (NEO), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at 0.01. The debt to equity ratio resting at 0.68. The interest coverage ratio of the stock is -13.41.
Currently, EBITDA for the company is -1.51 million with net debt to EBITDA at -2780.51. When we switch over and look at the enterprise to sales, we see a ratio of 0.67. The receivables turnover for the company is 4.45for trailing twelve months and the total asset turnover is 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.05.
Conclusion
In summary, Neogenomics Inc (NEO) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
